Premix 50/50 İnsulin ile premix 70/30 İnsuline kiyasla daha İyi glisemik kontrol mümkündür

Objective: Since only a small proportion of diabetics achieve optimal glycemic targets, intensification of treatment with insulin is needed in most of the cases. Application of insulin lispro premix 50/50 TID provides better glycemic control compared to human insulin premix 70/30 and comparable results reported with basal-bolus insulin regimen. The aim of this study was to determine the effect of insulin lispro premix 50/50 TID (Group 1, n=60) in comparison with insulin aspart premix 70/30 (Group 2, n=62). Materials and Methods: Type 2 diabetic patients, who were started on insulin treatment for the first time, were screened retrospectively. Change in A1C levels, 4-point self-monitored blood glucose measurements and rate of hypoglycemia within a 3-month period were recorded. Results: Basal A1C levels were higher (p=0.002) and the rate of improvement was greater in patients of Group 1 than in Group 2 patients (p=0.0006). There was no difference between the patients in achieving target A1C level and in the rate of hypoglycemia. A greater decrease in postprandial blood glucose level was achieved in patients of Group 1 (p<0.0001). Conclusion: Compared to insulin aspart premix 70/30, insulin lispro premix 50/50 provided better glycemic control without increasing the risk of hypoglycemia.